The basic framework of these settlements is: a) the generic-drug companies who settled can launch limited quantities their Revilimid generics in the US market in 2022 (Mar 2022 for Natco [the first company to settle with BMY]; and somewhat later in 2022 for RDY, Cipla, and Sun Pharma); and 2) the generic-drug companies who settled can launch unlimited quantities of their Revlimid generics starting on 1/31/26.